Tech Company Financing Transactions

NextCure Funding Round

Hillhouse Capital Group, Quan Capital and Alexandria Venture Investments joined a $93 million Series B funding round for NextCure. The round was recorded on 11/14/2018.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The proceeds will be primarily used to support clinical development for the company's two lead drug candidates, including NC318, preclinical development of additional novel immunomedicine drug candidates, and the Company's activities under its previously announced collaboration with Eli Lilly and Company to discover and develop novel cancer targets with the Company's proprietary FIND-IO platform.

Company Information

Company Status
Mailing Address
9000 Virginia Manor Rd. 200
New Haven, CT 20705
Email Address
NextCure (Nasdaq: NXTC), launched in 2015, is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
NextCure LinkedIn Company Profile
Social Media
NextCure Company Twitter Account
Company News
NextCure News
NextCure on Facebook
NextCure on YouTube

Management Team

Email & Social
Chief Executive Officer
Michael Richman
  Michael Richman LinkedIn Profile  Michael Richman Twitter Account  Michael Richman News  Michael Richman on Facebook
Chief Financial Officer
Steven Cobourn
  Steven Cobourn LinkedIn Profile  Steven Cobourn Twitter Account  Steven Cobourn News  Steven Cobourn on Facebook
Vice President
Linda Liu
  Linda Liu LinkedIn Profile  Linda Liu Twitter Account  Linda Liu News  Linda Liu on Facebook
VP - Bus. Development
James Bingham
  James Bingham LinkedIn Profile  James Bingham Twitter Account  James Bingham News  James Bingham on Facebook
VP - Bus. Development
Sebastien Maloveste
  Sebastien Maloveste LinkedIn Profile  Sebastien Maloveste Twitter Account  Sebastien Maloveste News  Sebastien Maloveste on Facebook
VP - Bus. Development
Timothy Mayer
  Timothy Mayer LinkedIn Profile  Timothy Mayer Twitter Account  Timothy Mayer News  Timothy Mayer on Facebook
VP - Regulatory Affairs
Sol Langermann
  Sol Langermann LinkedIn Profile  Sol Langermann Twitter Account  Sol Langermann News  Sol Langermann on Facebook



Browse more venture capital transactions:

Prev: 11/14/2018: CoverCress venture capital transaction
Next: 11/14/2018: AsclepiX Therapeutics venture capital transaction


Share this article


Where The Data Comes From

We do our best to record tech company VC transactions. VC transactions reported here come from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary